ArticleBlood advances2022

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.

Jennifer S Whangbo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.